Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis

被引:18
作者
Chen, Lin-Lin [1 ]
Zou, Yi-You [1 ]
Lu, Fang-Gen [2 ]
Li, Fu-Jun [1 ]
Lian, Guang-Hui [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 2, Dept Gastroenterol, Changsha 410011, Hunan, Peoples R China
关键词
Lactobacillus acidophilus; Bifidobacterium; Colonic flora; Therapeutic dose; Experimental colitis; Efficacy profile; VSLNUMBER-3; PROBIOTIC-MIXTURE; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; BIFIDOBACTERIUM; PATHOGENESIS; REMISSION; BACTERIAL; THERAPY; CASEI; GUT;
D O I
10.3748/wjg.v19.i32.5347
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To determine the efficacy profiles of different concentrations of Lactobacillus acidophilus (L. acidophilus) for treating colitis using an experimental murine model. METHODS: Colitis was established in 64 BALB/c mice by adding 5% dextran sodium sulfate (DSS) to the drinking water and allowing ad libitum access for 7 d. The mice were then randomly divided into the following control and experimental model groups (n = 8 each; day 0): untreated model control; negative-treatment model control (administered gavage of 1 mL/10 g normal saline); experimental-treatment models C4-C8 (administered gavage of 10(4), 10(5), 10(6), 10(7), or 10(8) CFU/10 g L. acidophilus, respectively); positive-treatment model control (administration of the anti-inflammatory agent prednisone acetate at 45 mu g/10 g). Eight mice given regular water (no DSS) and no subsequent treatments served as the normal control group. Body weight, fecal traits, and presence of fecal occult blood were assessed daily. All animals were sacrificed on post-treatment day 7 to measure colonic length, perform histological scoring, and quantify the major bacteria in the proximal and distal colon. Intergroup differences were determined by one-way ANOVA and post-hoc Student-Newman-Keuls comparison. RESULTS: All treatments (L. acidophilus and prednisone acetate) protected against colitis-induced weight loss (P < 0.05 vs model and normal control groups). The extent of colitis-induced colonic shortening was significantly reduced by all treatments (prednisone acetate > C4 > C5 > C7 > C8 > C6; P < 0.05 vs untreated model group), and the C6 group showed colonic length similar to that of the normal control group (P > 0.05). The C6 group also had the lowest disease activity index scores among the model groups. The bacterial profiles in the proximal colon were similar between all of the experimental-treatment model groups (all P > 0.05). In contrast, the bacterial profile in the distal colon of the C6 group showed the distinctive features (P < 0.05 vs all other experimental-treatment model groups) of Lactobacillus sp. and Bifidobacterium sp. being the most abundant bacteria and Staphylococcus aureus being the least abundant bacteria. CONCLUSION: The most therapeutically efficacious concentration of L. acidophilus (106 CFU/10 g) may exert its effects by modulating the bacterial profile in the distal colon. c 2013 Baishideng. All rights reserved.
引用
收藏
页码:5347 / 5356
页数:10
相关论文
共 35 条
  • [1] VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis
    Bibiloni, R
    Fedorak, RN
    Tannock, GW
    Madsen, KL
    Gionchetti, P
    Campieri, M
    De Simone, C
    Sartor, RB
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (07) : 1539 - 1546
  • [2] Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases
    Chapman, Therese M.
    Plosker, Greg L.
    Figgitt, David P.
    [J]. BIODRUGS, 2007, 21 (01) : 61 - 63
  • [3] VSL#3 probiotic mixture - A review of its use in chronic inflammatory bowel diseases
    Chapman, Therese M.
    Plosker, Greg L.
    Figgitt, David P.
    [J]. DRUGS, 2006, 66 (10) : 1371 - 1387
  • [4] Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease
    Conte, M. P.
    Schippa, S.
    Zamboni, I.
    Penta, M.
    Chiarini, F.
    Seganti, L.
    Osborn, J.
    Falconieri, P.
    Borrelli, O.
    Cucchiara, S.
    [J]. GUT, 2006, 55 (12) : 1760 - 1767
  • [5] Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385
  • [6] Future of IBD Pathogenesis: How Much Work Is Left to Do?
    Fiocchi, Cloudio
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 : S145 - S147
  • [7] Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis
    Furuta, Ryuichi
    Ando, Takafumi
    Watanabe, Osamu
    Maeda, Osamu
    Ishiguro, Kazuhiro
    Ina, Kenji
    Kusugami, Kazuo
    Goto, Hidemi
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (02) : 261 - 267
  • [8] Gardlik R, 2012, FOLIA BIOL-PRAGUE, V58, P238
  • [9] High-dose probiotics for the treatment of active pouchitis
    Gionchetti, Paolo
    Rizzello, Fernando
    Morselli, Claudia
    Poggioli, Gilberto
    Tambasco, Rosi
    Calabrese, Carlo
    Brigidi, Patrizia
    Vitali, Beatrice
    Straforini, Giulia
    Campieri, Massimo
    [J]. DISEASES OF THE COLON & RECTUM, 2007, 50 (12) : 2075 - 2082
  • [10] Increased Short- and Long-Term Risk of Inflammatory Bowel Disease After Salmonella or Campylobacter Gastroenteritis
    Gradel, Kim O.
    Nielsen, Hans L.
    Schonheyder, Henrik C.
    Ejlertsen, Tove
    Kristensen, Brian
    Nielsen, Henrik
    [J]. GASTROENTEROLOGY, 2009, 137 (02) : 495 - 501